SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-15-003798
Filing Date
2015-05-06
Accepted
2015-05-06 16:06:42
Documents
10
Period of Report
2015-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mrtx-20150331x10q.htm 10-Q 677092
2 EXHIBIT 31.1 mrtx33115ex311.htm EX-31.1 12050
3 EXHIBIT 31.2 mrtx33115ex312.htm EX-31.2 12952
4 EXHIBIT 32.1 mrtx33115ex321.htm EX-32.1 7899
  Complete submission text file 0001628280-15-003798.txt   3977840

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT mrtx-20150331.xml EX-101.INS 612638
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20150331.xsd EX-101.SCH 23732
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20150331_cal.xml EX-101.CAL 45735
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20150331_def.xml EX-101.DEF 60164
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20150331_lab.xml EX-101.LAB 279624
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20150331_pre.xml EX-101.PRE 151048
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35921 | Film No.: 15836988
SIC: 2834 Pharmaceutical Preparations